Evidence at the population level shows that giving oral anticoagulants has a clear long-term benefit in preventing recurrent ischaemic stroke in people with ischaemic stroke and atrial fibrillation. However, when it comes to an individualised treatment decision, many doctors are still reluctant to prescribe oral anticoagulants because of the associated risk of bleeding. We can be, as one of my colleagues says, "haemophobic". Intracranial haemorrhage associated with use of oral anticoagulants is indeed a serious condition but the benefit of oral anticoagulation has to be considered. A clinician will remember their last case of intracranial haemorrhage, but will not be able to count the ischaemic strokes they have prevented by prescription of oral anticoagulants.
Risks assessment scores, such as CHA₂DS₂VASc 1 or HAS-BLED, 2 are available to help clinicians to quantify risks of either ischaemic stroke or bleeding. Unfortunately, to date, such scores have not included brain imaging biomarkers. To personalise treatment and decrease the risk of intracranial haemorrhage, a clinician needs to also assess the brain, for which MRI is a brilliant tool.
Cerebral microbleeds are radiological constructs, first observed and defined using MRI, that correspond to perivascular focal collections of haemosiderin deposits resulting from small self-limiting haemorrhages. 3 In the context of cerebrovascular disease, cerebral microbleeds are now regarded as biomarkers of the severity of the underlying cerebrovascular disease. 4 In daily clinical practice, detection of cerebral microbleeds can trigger therapeutic dilemmas, such as starting antithrombotic agents. While cerebral microbleeds have been described as potential predictors of future intracranial haemorrhage in a recent post-hoc aggregatedata meta-analysis, 5 they are also considered to be biomarkers of future ischaemic events.
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In The Lancet Neurology, Duncan Wilson and colleagues report results from CROMIS-2, 7 an observational cohort study of 1447 people with ischaemic stroke or transient ischaemic attack and atrial fibrillation who were identified for treatment with oral anticoagulants. During a mean follow-up of 850 days, 14 symptomatic intracranial haemorrhages and 56 recurrent ischaemic strokes occurred. The presence of cerebral microbleeds, as assessed by MRI, was independently associated with the risk of future intracranial haemorrhage but not with the risk of ischaemic stroke. However, the absolute rate of recurrent ischaemic stroke was much higher than the absolute rate of intracranial haemorrhage irrespective of the presence of microbleeds. Besides the presence of cerebral microbleeds, the investigators found that participants with diabetes have an increased risk of intracranial haemorrhage compared with participants without diabetes. This result is of interest because people with diabetes are mostly considered at risk of ischaemic events.
Data from CROMIS-2 will help to inform clinicians of the risk of intracranial haemorrhage. In participants with at least one cerebral microbleed, the risk of intracranial haemorrhage was three times higher than in participants without them. The key question therefore is does this risk outweigh the benefit of oral anticoagulation in preventing a new ischaemic stroke? Probably not, but owing to its observational design, CROMIS-2 cannot definitively answer this question. Moreover, despite the large collaborative effort across 80 hospitals to maximise the size of the cohort, only 14 intracranial haemorrhages occurred and more than half of the study participants were treated with vitamin K antagonists, which are likely to be associated with a higher risk of intracranial haemorrhage than are direct oral anticoagulants. 8 Finally, because the CROMIS-2 study focused on secondary prevention, their results cannot be extrapolated to the primary prevention setting in which systematic brain MRI screening is not recommended before starting oral anticoagulation in people with atrial fibrillation.
The pragmatic message from this study that can be brought to every doctor's next ward round is that although people with cerebral microbleeds are at risk of intracranial haemorrhage, they are also at high risk of ischaemic stroke. Although presence of microbleeds can be informative, counting microbleeds on an MRI is not good enough: clinicians should carefully assess the brain as a whole and go beyond the micro scope of microbleeds. Cerebral microbleeds are just one element of an underlying vessel disease, so to carefully evaluate the risk of future bleeding, clinicians need to find the cause of the ongoing vessel disease. Is it deep perforating vasculopathy? Is it cerebral amyloid angiopathy? In this quest, other parameters might be worth evaluating in future risk scores such as APOE allele status, extent and distribution of white matter lesions, or cognitive performance. The disease penetrance is incomplete, with some GRN carriers remaining asymptomatic at advanced ages. 4 In their study reported in The Lancet Neurology, Cyril Pottier and colleagues 5 aim to identify genomic loci associated with disease heterogeneity in a large cohort of GRN carriers using genome-wide association analyses. They did not find a significant association between any genetic variant and age at onset, but did confirm the previously reported association between TMEM106B and disease risk. 6 Most interesting was their identification on chromosome 8 of a novel risk locus at GFRA2, encoding a member of the GDNF receptor family. In the discovery stage, Pottier and colleagues analysed 382 symptomatic GRN carriers and 1146 con trols without neurodegenerative disorders, and identified a suggestive association between genetic variants in the GFRA2 locus and disease risk. Subsequent analysis in the replication stage (involving 67 symptomatic GRN carriers, 143 patients with FTLD-TDP type A pathology but without GRN mutations, and 1798 controls free of neurodegenerative diseases), revealed a significant association in the GFRA2 locus, which remained significant in the meta-analysis of the discovery and replication data. Patients with FTLD-TDP type A pathology without GRN mutations also contributed to the association, suggesting that GFRA2 contributes to disease risk in a larger group of patients with FTLD. Pottier and colleagues also did expression studies in cerebellar tissue, and found that transcript levels of GFRA2 were reduced in carriers who were homozygous for the minor allele of the lead risk variant, compared with carriers who were homozygous for the major allele. In-vitro studies implied a direct interaction between GFRA2 and GRN, although more functional
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